IRIS
CRISCITIELLO, Carmen
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 907
NA - Nord America 884
EU - Europa 306
Continente sconosciuto - Info sul continente non disponibili 207
SA - Sud America 171
AF - Africa 39
Totale 2.514
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 795
SG - Singapore 300
CN - Cina 236
IT - Italia 144
BR - Brasile 120
VN - Vietnam 115
IN - India 53
HK - Hong Kong 37
FR - Francia 35
BD - Bangladesh 33
CA - Canada 29
MX - Messico 24
GB - Regno Unito 23
AR - Argentina 22
IQ - Iraq 19
SA - Arabia Saudita 17
TR - Turchia 17
DE - Germania 15
ID - Indonesia 13
PL - Polonia 12
ES - Italia 11
PK - Pakistan 11
JM - Giamaica 10
DZ - Algeria 9
RU - Federazione Russa 9
IE - Irlanda 8
MY - Malesia 8
PH - Filippine 8
ZA - Sudafrica 8
CL - Cile 7
EC - Ecuador 7
FI - Finlandia 7
UA - Ucraina 7
MA - Marocco 6
PT - Portogallo 6
CO - Colombia 5
EG - Egitto 5
SV - El Salvador 5
TH - Thailandia 5
BE - Belgio 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
GT - Guatemala 4
JP - Giappone 4
PE - Perù 4
SE - Svezia 4
TW - Taiwan 4
VE - Venezuela 4
AE - Emirati Arabi Uniti 3
AZ - Azerbaigian 3
CZ - Repubblica Ceca 3
JO - Giordania 3
NL - Olanda 3
RO - Romania 3
SN - Senegal 3
UZ - Uzbekistan 3
AT - Austria 2
BB - Barbados 2
CH - Svizzera 2
ET - Etiopia 2
GR - Grecia 2
IL - Israele 2
KW - Kuwait 2
LB - Libano 2
NG - Nigeria 2
NI - Nicaragua 2
NP - Nepal 2
PA - Panama 2
PR - Porto Rico 2
AL - Albania 1
BG - Bulgaria 1
BT - Bhutan 1
CD - Congo 1
CI - Costa d'Avorio 1
HU - Ungheria 1
KG - Kirghizistan 1
LA - Repubblica Popolare Democratica del Laos 1
LV - Lettonia 1
MN - Mongolia 1
MQ - Martinica 1
MW - Malawi 1
MZ - Mozambico 1
NO - Norvegia 1
OM - Oman 1
PS - Palestinian Territory 1
PY - Paraguay 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 2.308
Salva come PNG Salva come JPEG
Città #
Council Bluffs 211
Singapore 97
Santa Clara 85
Beijing 83
Ashburn 42
San Jose 40
Hong Kong 35
Milan 34
Ho Chi Minh City 32
Los Angeles 25
Hanoi 21
New York 21
Rome 19
Buffalo 18
Phoenix 14
Dallas 13
The Dalles 13
Assago 12
Mexico City 11
São Paulo 11
Da Nang 10
Orem 10
Lorton 9
Shanghai 8
Frankfurt am Main 7
Hillsboro 7
Naples 7
Seattle 7
Cincinnati 6
Geneva 6
Helsinki 6
London 6
Paris 6
Rio de Janeiro 6
Riyadh 6
Warsaw 6
Baghdad 5
Boardman 5
Dammam 5
Figino 5
Houston 5
Istanbul 5
Jeddah 5
Kuala Lumpur 5
Madrid 5
Maynooth 5
Montreal 5
New Delhi 5
Atlanta 4
Belo Horizonte 4
Chennai 4
Dhaka 4
Durban 4
Englewood 4
Florence 4
Kingston 4
Lahore 4
Modena 4
Mumbai 4
Padua 4
Phú Thọ 4
Quito 4
San Antonio 4
San Salvador 4
Santiago 4
Toronto 4
Turin 4
Valencia 4
Wayne 4
Auburn 3
Baku 3
Bangkok 3
Barnet 3
Batna City 3
Bexley 3
Bogotá 3
Brooklyn 3
Cairo 3
Casablanca 3
Charlotte 3
Cherry Hill 3
Columbus 3
Dakar 3
Dublin 3
East Brunswick 3
Gilbert 3
Guatemala City 3
Hyderabad 3
Hải Dương 3
Jacksonville 3
Lima 3
Manchester 3
Miami 3
Palermo 3
Philadelphia 3
Queens 3
Richmond 3
San Francisco 3
Surat 3
Tashkent 3
Totale 1.187
Salva come PNG Salva come JPEG
Nome #
Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM) 60
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 47
PARP-inhibitors for BRCA1/2-related advanced HER2-negative breast cancer: A meta-analysis and GRADE recommendations by the Italian Association of Medical Oncology 44
Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer 43
Nipple sparing mastectomy as a risk‐reducing procedure for brca‐mutated patients 43
Should oncoplastic breast conserving surgery be used for the treatment of early stage breast cancer? Using the GRADE approach for development of clinical recommendations 41
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study 36
Global cancer control: responding to the growing burden, rising costs and inequalities in access 34
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials 30
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey 28
PARP Inhibitors for Breast Cancer Treatment 28
Survival Following CDK4/6 Inhibitor Therapy for Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer 25
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors 25
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer 23
A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+ PIK3CA-mutated breast cancer 22
Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care 22
Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021 21
Genomic and clinical landscape of metastatic hormone receptors-positive breast cancers carrying ESR1 alterations 20
Association between baseline tumour burden and outcome in patients with cancer treated with next-generation immunoncology agents 19
Advancing equitable and personalized cancer care: Novel applications and priorities of artificial intelligence for fairness and inclusivity in the patient care workflow 19
Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution 19
Tumori maligni del colon 19
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials 19
Dendritic cell-based vaccines : clinical applications in breast cancer 19
Tumor-infiltrating lymphocytes (TILs) in ER+/HER2− breast cancer 18
Successes and limitations of targeted cancer therapy in breast cancer 18
Pharmacological management of male breast cancer 18
Characterization of low HER2 expressions in de-novo metastatic breast cancer 18
Expert recommendations on treatment sequencing and challenging clinical scenarios in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer 17
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy 17
Impact of Rehabilitation on Breast Cancer Related Fatigue : A Pilot Study 17
Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation 17
Safety of covid-19 mrna vaccines in patients with cancer enrolled in early-phase clinical trials 17
Assessment of estrogen receptor low positive status in breast cancer: Implications for pathologists and oncologists 16
Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine 16
Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma in Situ, Metastatic Tumor Deposits and Areas for Further Research 16
A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer 16
Immune checkpoint inhibitors for patients with metastatic triple-negative inflammatory breast cancer (INCORPORATE): An international cohort study 16
Neoadjuvant model for testing emerging targeted therapies in breast cancer 16
Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status 16
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics 16
Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial 16
Over-using chemotherapy in the adjuvant setting 16
Variant allele frequency: a decision-making tool in precision oncology? 16
Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00 15
A multidisciplinary approach to an unusual medical case of locally advanced gastric cancer: a case report 15
Health-Related Quality of Life Among Patients With HR+/HER2- Early Breast Cancer 15
Immunotherapy of Breast Cancer 14
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? 14
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 14
Adjuvant treatment of early male breast cancer 14
Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars : a physician survey in the united states and emerging markets 14
Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer 14
Molecular tumour board at European Institute of Oncology: Report of the first three year activity of an Italian precision oncology experience 14
Tumor-stroma crosstalk: targeting stroma in breast cancer 14
Bowel obstruction and peritoneal carcinomatosis in the elderly. A systematic review 14
Immunotherapeutics for breast cancer 14
Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy 13
[Exemestane in the treatment of breast carcinoma: recent findings] 13
Antibody–drug conjugates in solid tumors: a look into novel targets 13
HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer 13
Immune checkpoint inhibitors with radiotherapy and locoregional treatment : synergism and potential clinical implications 13
Deep learning algorithm on H&E whole slide images to characterize TP53 alterations frequency and spatial distribution in breast cancer 13
Follow-up of early breast cancer in a public health system: A 2024 AIGOM consensus project 12
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer 12
Evolution of low HER2 expression between early and advanced-stage breast cancer 12
The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario? 12
Metastasis-directed stereotactic radiotherapy and systemic treatment continuation for patients with oligoprogressive metastatic breast cancer 12
Pten alterations and their role in cancer management: Are we making headway on precision medicine? 12
Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines 12
RNAi screens identify CHD4 as an essential gene in breast cancer growth 12
Maximizing the Clinical Benefit of Anthracyclines in Addition to Taxanes in the Adjuvant Treatment of Early Breast Cancer 12
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials 11
Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study 11
Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment 11
Targeting fibroblast growth factor receptor pathway in breast cancer 11
Targeting the subtypes of breast cancer: Rethinking investigational drugs 11
Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art 11
Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls 11
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer 11
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer : results from Neo-ALTTO 10
HER2-positive circulating tumor cells in breast cancer 10
Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence 10
Breast Cancer with Brain Metastasis: Molecular Insights and Clinical Management 10
Estrogen Signaling in Early-Stage Breast Cancer: Impact on Neoadjuvant Chemotherapy and Immunotherapy 10
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials 10
Best management of locally advanced inoperable breast cancer 10
Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management 10
Factors associated with surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial 10
Breast Cancer with Bone Metastasis: Molecular Insights and Clinical Management 10
ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer 10
Targeted therapies in breast cancer: are heart and vessels also being targeted? 10
Subtype-Specific Metabolic Patterns in Staging Breast Cancer: Insights from Conventional and Parametric PET Radiomics 10
QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review 10
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014 10
Understanding the biology of triple-negative breast cancer 10
Targeting brain metastases in breast cancer 10
Locoregional recurrence in patients with HER2 positive breast cancer 10
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer 10
The Safety and Suitability of DNA Sequencing of Tissue Biopsies Performed on Patients Referred to a Phase I Unit 10
Totale 1.698
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.289
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.289
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224 0 0 0 0 0 0 0 0 2 0 2 0
2022/202318 4 0 2 0 1 0 0 0 2 8 1 0
2023/202414 0 2 3 1 0 0 0 1 1 1 3 2
2024/202559 0 2 2 0 1 7 3 2 10 19 6 7
2025/20261.780 28 4 9 19 4 4 41 803 343 255 135 135
2026/2027639 344 295 0 0 0 0 0 0 0 0 0 0
Totale 2.514